Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 47 contracts
Samples: Securities Purchase Agreement (Entrada Therapeutics, Inc.), Securities Purchase Agreement (Century Therapeutics, Inc.), Securities Purchase Agreement (Ocular Therapeutix, Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 21 contracts
Samples: Securities Purchase Agreement (Madrigal Pharmaceuticals, Inc.), Purchase Agreement (SharpSpring, Inc.), Registration Rights Agreement (Madrigal Pharmaceuticals, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s 's Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s 's Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 7 contracts
Samples: Registration Rights Agreement (Zila Inc), Security Agreement (Zila Inc), Purchase Agreement (LOCAL.COM)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq NASDAQ continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq NASDAQ and the Company has not received any notice of, nor nor, to the Company’s Knowledge Knowledge, is there any reasonable basis for, the delisting of the Common Stock from NasdaqNASDAQ.
Appears in 5 contracts
Samples: Securities Purchase Agreement (Spectrum Pharmaceuticals Inc), Securities Purchase Agreement (Inseego Corp.), Securities Purchase Agreement (Inseego Corp.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq National Market continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq National Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 5 contracts
Samples: Purchase Agreement (Ursus Telecom Corp), Purchase Agreement (Visionics Corp), Purchase Agreement (Nexmed Inc)
Compliance with Nasdaq Continued Listing Requirements. The Except as disclosed in the SEC Filings, (a) the Company is in compliance with applicable Nasdaq continued listing requirements. There , (b) there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq Nasdaq, and (c) the Company has not received any currently pending notice of, nor to the Company’s Knowledge is there any reasonable basis for, of the delisting of the Common Stock from Nasdaq.
Appears in 5 contracts
Samples: Purchase Agreement (PLx Pharma Inc.), Purchase Agreement (PLx Pharma Inc.), Subordination Agreement (Overland Storage Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 4 contracts
Samples: Purchase Agreement (Insignia Systems Inc/Mn), Purchase Agreement (Rainmaker Systems Inc), Purchase Agreement (Conductus Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq NASDAQ continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq NASDAQ and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from NasdaqNASDAQ.
Appears in 4 contracts
Samples: Stock Purchase Agreement (Tokai Pharmaceuticals Inc), Securities Purchase Agreement (Ardelyx, Inc.), Securities Purchase Agreement (Ardelyx, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Except as described in the SEC Filings, the Company is in compliance with applicable Nasdaq continued listing requirements. There Except as described in the SEC Filings, there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 4 contracts
Samples: Purchase Agreement (Selectica Inc), Purchase Agreement (Selectica Inc), Purchase Agreement (Selectica Inc)
Compliance with Nasdaq Continued Listing Requirements. The Except as disclosed in the SEC Filings, (i) the Company is in compliance with applicable Nasdaq continued listing requirements. There , (ii) there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock Shares on Nasdaq Nasdaq, and (iii) the Company has not received any currently pending notice of, nor to the Company’s Knowledge is there any reasonable basis for, of the delisting of the Common Stock Shares from Nasdaq.
Appears in 4 contracts
Samples: Subscription Agreement (Sphere 3D Corp), Subscription Agreement (Sphere 3D Corp), Purchase Agreement (Sphere 3D Corp)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock Ordinary Shares on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock Ordinary Shares from Nasdaq.
Appears in 3 contracts
Samples: Securities Purchase Agreement (MeiraGTx Holdings PLC), Securities Purchase Agreement (MeiraGTx Holdings PLC), Securities Purchase Agreement (MeiraGTx Holdings PLC)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 3 contracts
Samples: Securities Purchase Agreement (Orgenesis Inc.), Securities Purchase Agreement (Orgenesis Inc.), Securities Purchase Agreement (Orgenesis Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock Shares on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock Shares from Nasdaq.
Appears in 3 contracts
Samples: Investment Agreement (CRISPR Therapeutics AG), Securities Purchase Agreement (Centogene N.V.), Securities Purchase Agreement (Establishment Labs Holdings Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Except as described on Schedule 4.20, the Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s Common Stock on Nasdaq and the Company has not received any notice of, nor nor, except as described on Schedule 4.20, to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 2 contracts
Samples: Purchase Agreement (Tarantella Inc), Purchase Agreement (Tarantella Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, or threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 2 contracts
Samples: Personalis, Inc., Personalis, Inc.
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance in all material respects with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any written notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 2 contracts
Samples: Purchase Agreement (Remark Media, Inc.), Purchase Agreement (Remark Media, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Except as described on Schedule 4.20, the Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 2 contracts
Samples: Form of Purchase Agreement (Response Genetics Inc), Purchase Agreement (Pfsweb Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the The Company has not received any written notice of, nor with respect to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 2 contracts
Samples: Common Stock and Warrant Purchase Agreement (Sunesis Pharmaceuticals Inc), Common Stock and Warrant Purchase Agreement (Sunesis Pharmaceuticals Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq NasdaqCM continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq NasdaqCM and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from NasdaqNasdaqCM. To the Company’s Knowledge, there are no facts or circumstances which might give rise to any of the foregoing.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Celsion CORP), Securities Purchase Agreement (Celsion CORP)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq NasdaqCM continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and NasdaqCM and, except as disclosed in the SEC Filings, the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from NasdaqNasdaqCM.
Appears in 2 contracts
Samples: Purchase Agreement (Celsion CORP), Purchase Agreement (Celsion CORP)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There Except as described in Schedule 4.20, there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 2 contracts
Samples: Purchase Agreement (Planetout Inc), Purchase Agreement (Meade Instruments Corp)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq Capital Market continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on the Nasdaq Capital Market and the Company has not received any currently effective notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Capital Market.
Appears in 2 contracts
Samples: Common Stock Purchase Agreement (Peregrine Pharmaceuticals Inc), Common Stock Purchase Agreement (Peregrine Pharmaceuticals Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq Stock Market, LLC continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on The Nasdaq Global Select Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from NasdaqThe Nasdaq Global Select Market.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Aimmune Therapeutics, Inc.), Securities Purchase Agreement (Aimmune Therapeutics, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Except as described in the SEC Filings, the Company is in compliance with applicable Nasdaq continued listing requirements. There Except as described in the SEC Filings, there are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 2 contracts
Samples: Securities Purchase Agreement (Seres Therapeutics, Inc.), Form of Securities Purchase Agreement (Seres Therapeutics, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the The Company has not received any written notice of, nor with respect to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Global Market.
Appears in 2 contracts
Samples: Common Stock and Warrant Purchase Agreement (Ats Medical Inc), Common Stock and Warrant Purchase Agreement (Ats Medical Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company To the Company’s Knowledge, after due inquiry, it is in compliance with applicable all Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and Nasdaq, and, the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Securities Purchase Agreement (Eliem Therapeutics, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in material compliance with all applicable Nasdaq National Market continued listing requirementsrequirements and is in good standing on such exchange. There are no proceedings pending or, to the Company’s Knowledge's knowledge, threatened against the Company relating to the continued listing of the Common Stock on the Nasdaq National Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s 's Knowledge, threatened against the Company relating to the continued listing of the Company's Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s 's Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq National Market continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, or threatened against the Company relating to the continued listing of the Common Stock on the Nasdaq National Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Except as disclosed in the SEC Documents, the Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s Common Stock on Nasdaq and except as disclosed on Schedule 4.20, the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor nor, to the Company’s Knowledge Knowledge, is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The ------------------------------------------------------- Company is in compliance with all applicable Nasdaq continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq National Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 1 contract
Samples: Purchase Agreement (Lifecell Corp)
Compliance with Nasdaq Continued Listing Requirements. The Except as described in Schedule 4.20, the Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s 's Knowledge, threatened against the Company relating to the continued listing of the Company's Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s 's Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Purchase Agreement (Starbase Corp)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s 's Knowledge, threatened against the Company relating to the continued listing of the Company's Common Stock on Nasdaq and the Company has not received any unremedied notice of, nor to the Company’s 's Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any currently pending notice of, nor relating to the Company’s Knowledge is there any reasonable basis for, compliance with Nasdaq’s continued listing requirements or the potential delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Purchase Agreement (Glu Mobile Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq National Market continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s Common Stock on the Nasdaq National Market and the Company has not received any currently effective notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 1 contract
Samples: Purchase Agreement (Audible Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq National Market continued listing requirementsrequirements and is in good standing on such exchange. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq National Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 1 contract
Samples: Purchase Agreement This Purchase Agreement (Clickaction Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, or threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Securities Purchase Agreement (vTv Therapeutics Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirementsrequirements in all material respects. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge's knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge 's knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq Capital Market continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, knowledge threatened against the Company relating to the continued listing of the Company’s Common Stock on the Nasdaq Capital Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Capital Market.
Appears in 1 contract
Samples: Purchase Agreement (Nexmed Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock Shares on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock Shares from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq Stock Market continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on the Nasdaq Capital Market and the Company has not received any currently effective notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Capital Market. The Shares have been approved for listing on the Nasdaq stock market.
Appears in 1 contract
Samples: Common Stock Purchase Agreement (Peregrine Pharmaceuticals Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements and the execution, delivery and Exhibit 10.1 performance by the Company of the Transaction Documents and the offer, issuance and delivery of the Closing Securities will not violate applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Securities Purchase Agreement (Innovate Biopharmaceuticals, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any written notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq SmallCap Market.
Appears in 1 contract
Samples: Purchase Agreement (Tegal Corp /De/)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s 's Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any written notice of, nor to the Company’s 's Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Purchase Agreement (Telular Corp)
Compliance with Nasdaq Continued Listing Requirements. The As of the date hereof, the Company is in compliance with applicable Nasdaq continued listing requirements. There requirements and there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s Common Stock on Nasdaq and Nasdaq. In the two years preceding the date hereof, the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements and the execution, delivery and performance by the Company of the Transaction Documents and the offer, issuance and delivery of the Closing Securities will not violate applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Securities Purchase Agreement (Aileron Therapeutics Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq Small-Cap Market continued listing requirementsrequirements and is in good standing on such exchange. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq Small-Cap Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Small-Cap Market.
Appears in 1 contract
Samples: Purchase Agreement (Fonar Corp)
Compliance with Nasdaq Continued Listing Requirements. The Except as described on Schedule 4.20, the Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor except as set forth on Schedule 4.20 to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq SmallCap Market continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq and Smallcap Market and, except as set forth on Schedule 4.21, the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Smallcap Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Company’s Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq. The Company is in material compliance with NASD rules and regulations applicable to the Company.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq continued listing requirementsrequirements for the Nasdaq Stock Market. There are no proceedings pending or, to the Company’s Knowledge's knowledge, threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq Stock Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Stock Market.
Appears in 1 contract
Samples: Purchase Agreement (Sunrise Technologies International Inc)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq SmallCap Market continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq and Smallcap Market and, except as set forth on Schedule 4.21, the Company has not received any 8 9 notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Smallcap Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Except as described in Schedule 4.20, the Company is in compliance with applicable Nasdaq continued listing requirements. There Except as described in Schedule 4.20, there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq Small Cap Market continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq requirements and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the from Nasdaq concerning a possible delisting of the Company's Common Stock from Nasdaqwithin the last twelve months.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company ----------------------------------------------------- is in compliance with all applicable Nasdaq continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge's knowledge, threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq National Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq National Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Except as disclosed in the Registration Statement, (a) the Company is in compliance with applicable Nasdaq continued listing requirements. There , (b) there are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq Nasdaq, and (c) the Company has not received any currently pending notice of, nor to the Company’s Knowledge is there any reasonable basis for, of the delisting of the Common Stock from NasdaqNasdaq other than the notice of deficiency received by the Company on January 2, 2013.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq Stock Market, LLC continued listing requirements. There are no proceedings pending or, to the Company’s Knowledgeknowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq and the Company has not received any notice of, nor to the Company’s Knowledge knowledge is there any reasonable basis for, the delisting of the Common Stock from Nasdaq.
Appears in 1 contract
Samples: Securities Purchase Agreement (Seres Therapeutics, Inc.)
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with all applicable Nasdaq continued listing requirements. There are no proceedings pending or, or to the Company’s Knowledge, 's knowledge threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq SmallCap Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq SmallCap Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The ----------------------------------------------------- Company is in compliance with all applicable Nasdaq continued listing requirementsrequirements for the Nasdaq Stock Market. There are no proceedings pending or, to the Company’s Knowledge's knowledge, threatened against the Company relating to the continued listing of the Company's Common Stock on the Nasdaq Stock Market and the Company has not received any notice of, nor to the Company’s Knowledge knowledge of the Company is there any reasonable basis for, the delisting of the Common Stock from Nasdaqthe Nasdaq Stock Market.
Appears in 1 contract
Compliance with Nasdaq Continued Listing Requirements. The Company is in compliance with applicable Nasdaq NasdaqCM continued listing requirements. There are no proceedings pending or, to the Company’s Knowledge, threatened against the Company relating to the continued listing of the Common Stock on Nasdaq NasdaqCM and the Company has not received any notice of, nor to the Company’s Knowledge is there any reasonable basis for, the delisting of the Common Stock from NasdaqNasdaqCM.
Appears in 1 contract
Samples: Purchase Agreement (Celsion CORP)
